A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew Brunner, MD, of the Massachusetts General Hospital, Boston, MA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Stéphane de Botton, MD, PhD, of the Gustave Roussy Institute, Paris, France, and Andrius Zucenka, MD, of the Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, share updates on novel therapies for the treatment of AML, as presented at the European Hematology Association (EHA) 2021 congress.
The Lymphoma Sessions: highlights from ASH 2020
The MDS Sessions: Giants in MDS
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
VJSession: EBMT/EHA CAR-T Nursing Session
The Myeloma Sessions: key updates from ASH 2020
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Updates for the management of MDS from ASH 2020
The AML Sessions: highlights from ASH 2020
The MDS Sessions: treating MDS around the world
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
The MDS sessions: lower-risk disease
The AML Sessions: FLT3-mutated disease
The Lymphoma Sessions: highlights from iwNHL 2020
The MDS sessions: clinical trial participation, endpoints & approvals
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive